Results 71 to 80 of about 35,844 (219)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +2 more sources

Activated Protein C Resistance Testing: An Update From Australasia/Asia‐Pacific

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Activated protein C resistance (APCR) represents a risk factor for thrombosis and is usually due to factor V Leiden (FVL). Clinicians may order either test (i.e., APCR or FVL) to help assess ‘thrombophilia’ in patients who present with thrombosis. APCR testing is usually achieved using clot‐based assays, whereas FVL is assessed by
Emmanuel J. Favaloro, Sandya Arunachalam, Elysse Dean, Mahzuza Salwa, Monica Ahuja, Lynne Connelly, Kent Chapman, Ronny Vong, Leonardo Pasalic   +8 more
wiley   +1 more source

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.

PLoS ONE, 2012
BackgroundDabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost ...
Joyce H S You, Kia K N Tsui, Raymond S M Wong, Gergory Cheng   +3 more
doaj   +1 more source

Prior-preconditioned conjugate gradient method for accelerated Gibbs sampling in "large $n$ & large $p$" sparse Bayesian regression

, 2020
In a modern observational study based on healthcare databases, the number of observations and of predictors typically range in the order of $10^5$ ~ $10^6$ and of $10^4$ ~ $10^5$.
Nishimura, Akihiko, Suchard, Marc A.
core   +1 more source

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study [PDF]

, 2013
OBJECTIVE: Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. DESIGN: Pharmacoepidemiological cohort study.
Charlot, M., Fosbol, E. L., Gislason, G., Hansen, M. L., Hvidtfeldt, M. W., Karasoy, D., Kober, L., Lamberts, M., Lip, G. Y. H., Olesen, J. B., Sorensen, R., Torp-Pedersen, C., Weeke, P.   +12 more
core   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

Hemopericardium and Cardiac Tamponade Associated with Dabigatran Use [PDF]

, 2012
OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran. CASE SUMMARIES: A 70-year-old male with a history of dabigatran use presented with cough, fatigue, and bloody stools.
Dy, Eliza A., Shiltz, Dane L.
core   +2 more sources

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [PDF]

, 2014
Background: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown.
Ansell, Jack, Chang, Paul, Ezekowitz, Michael D., Fonarow, Gregg C., Gersh, Bernard, Holmes, DaJuanicia N., Hylek, Elaine M., Kowey, Peter R., Mahaffey, Kenneth W., Peterson, Eric D., Piccini, Jonathan P., Singer, Daniel E., Steinberg, Benjamin A., Thomas, Laine   +13 more
core   +1 more source

Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages

Internal Medicine Journal, EarlyView.
Abstract Background An increasing number of patients in Australia are taking direct oral anticoagulants for a variety of indications since their introduction in the treatment landscape. There has always been some concern about the optimal management approach in the setting of major and/or life‐threatening bleeding.
Sara Shu‐Ling Ng, Hashim Noori, Diem Nguyen, Zhengbang Wang, Danny Hsu   +4 more
wiley   +1 more source

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry

Therapeutic Advances in Neurological Disorders, 2014
Background: There are growing concerns for the side effects of dabigatran etexilate (dabigatran), including higher incidence of dyspepsia and gastrointestinal bleeding.
Georgios Tsivgoulis, Christos Krogias, Kara A. Sands, Vijay K. Sharma, Aristeidis H. Katsanos, Konstantinos Vadikolias, Sokratis G. Papageorgiou, Ioannis Heliopoulos, Harn Shiue, Athina Mitsoglou, Chrissoula Liantinioti, Dimitrios Athanasiadis, Sotirios Giannopoulos, Charitomeni Piperidou, Konstantinos Voumvourakis, Andrei V. Alexandrov   +15 more
doaj   +1 more source